- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01664039
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
July 13, 2015 updated by: Alcon Research
Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma
The purpose of this study is evaluate effects of TRAVATAN® versus LUMIGAN® on intraocular pressure (IOP) and ocular surface and inflammatory biomarkers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
104
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosed with either open-angle glaucoma or ocular hypertension in at least one eye and be treatment naïve to any glaucoma treatment.
- Intraocular pressure (IOP) between 19 mmHg and 35 mmHg in at least one eye, which would be the study eye.
- IOP considered to be safe (in the opinion of the investigator), in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period.
- Able to follow instructions and be willing and able to attend all study visits.
- Best corrected Snellen visual acuity of 6/60 (20/200, 1.0 LogMAR) or better in each eye.
- Must read, sign, and date an Ethics Committee-approved informed consent form.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Known medical history of allergy, hypersensitivity or poor tolerance to any components of the study medications to be used in this study that is deemed clinically significant in the opinion of the Principal Investigator.
- Any abnormality preventing reliable applanation tonometry in either eye.
- Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.
- Prior treatment of dry eye with punctal plugs, punctal cautery, Restasis® or topical ocular corticosteroids.
- History of ocular surface disease (dry eye) or current/prior use of dry eye medications (either over-the counter or prescription medications).
- Contact lens wear.
- Intraocular conventional surgery or laser surgery in either eye that is less than three months prior to the Screening Visit.
- Use of any systemic medications known to affect IOP (e.g., oral beta-adrenergic blockers, alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for at least 7 days prior to Screening Visit or an anticipated change in the dosage during the course of the study.
- Women of childbearing potential not using reliable means of birth control, are pregnant, or lactating.
- Unwilling to risk the possibility of darkened iris or eyelash changes.
- Participation in any other investigational study within 30 days prior to the Screening Visit.
- Other protocol-defined exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TRAVATAN
Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months
|
Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
Other Names:
|
Active Comparator: LUMIGAN
Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months
|
Ophthalmic solution containing benzalkonium chloride (BAK)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in Intraocular Pressure (IOP) at Month 6
Time Frame: Baseline (Day 0), Month 6
|
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg).
A more negative change indicates a greater amount of improvement.
One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
|
Baseline (Day 0), Month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in IOP at Week 6 and Month 3
Time Frame: Baseline (Day 0), Week 6, Month 3
|
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg.
A more negative change indicates a greater amount of improvement.
One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
|
Baseline (Day 0), Week 6, Month 3
|
Percentage of Subjects Who Reached Target IOP at Each Visit
Time Frame: Week 6, Month 3, Month 6
|
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg.
Target IOP was defined as ≤ 18 mmHg.
One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
|
Week 6, Month 3, Month 6
|
Number of Subjects With Change From Baseline in Ocular Hyperaemia by Grade at Each Visit
Time Frame: Baseline (Day 0), Week 6, Month 3, Month 6
|
Ocular Hyperaemia (excess of blood in the white of the eyes (sclera)) was graded by the investigator on a 4-point scale where 0=None/Trace, 1=Mild, 2=Moderate, and 3=Severe.
One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
|
Baseline (Day 0), Week 6, Month 3, Month 6
|
Number of Subjects With Change From Baseline in Corneal Staining by Grade at Month 3 and Month 6
Time Frame: Baseline (Day 0), Month 3, Month 6
|
Corneal staining was assessed after ophthalmic dye was instilled in the eye.
The upper eyelid was lifted slightly, and the eye was compared to grading panels.
Corneal staining was graded on a scale from 0 (absent) to 5 (severe).
One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
|
Baseline (Day 0), Month 3, Month 6
|
Number of Subjects With Change From Baseline in Conjunctiva Staining by Grade at Month 3 and Month 6
Time Frame: Baseline (Day 0), Month 3, Month 6
|
Conjunctiva staining was assessed after ophthalmic dye was instilled in the eye.
The upper eyelid was lifted slightly, and the eye was compared to grading panels.
Conjunctiva staining was graded on a scale from 0 (absent) to 5 (severe).
One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
|
Baseline (Day 0), Month 3, Month 6
|
Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Month 3 and Month 6
Time Frame: Baseline (Day 0), Month 3, Month 6
|
The OSDI questionnaire (used to measure vision-related function, ocular symptoms, visual function, and environmental factors that may affect vision) was answered by the subject.
Each of the 12 items was scored on a 0-4 Likert scale, where 0 is "None of the time" and 4 is "All of the time."
A resultant overall 0-100 score was calculated, with higher scores representing greater disability.
A negative number change represents a perceived improvement in ocular health.
|
Baseline (Day 0), Month 3, Month 6
|
Mean Change From Baseline In Tear Film Break Up Time (TBUT) at Month 3 and Month 6
Time Frame: Baseline (Day 0), Month 3, Month 6
|
TBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using slit lamp examination .
A longer break up time is a sign of a more stable tear film.
A positive number change from baseline indicates improvement.
One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
|
Baseline (Day 0), Month 3, Month 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Actual)
June 1, 2014
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
August 10, 2012
First Submitted That Met QC Criteria
August 10, 2012
First Posted (Estimate)
August 14, 2012
Study Record Updates
Last Update Posted (Estimate)
August 3, 2015
Last Update Submitted That Met QC Criteria
July 13, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RDG-11-244
- 2012-002078-30 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Santen Inc.Completed
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on Travoprost 0.004% ophthalmic solution
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Laboratorios Sophia S.A de C.V.Completed
-
Alcon ResearchCompletedOcular Hypertension | Open Angle Glaucoma
-
Alcon ResearchCompletedOcular Hypertension | Glaucoma
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Alcon ResearchCompletedOcular Hypertension | Open-angle Glaucoma
-
Kasr El Aini HospitalCompletedPrimary Open Angle GlaucomaEgypt
-
Alcon ResearchCompletedOcular Hypertension | Normal Tension GlaucomaJapan
-
Alcon ResearchTerminatedOcular Hypertension | Open-Angle Glaucoma